Alpha Teknova, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alpha Teknova, Inc. (Nasdaq: TKNO) on November 10, 2021. The filing reports the appointment of a new executive officer and related compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation details:
- Base Salary: $377,500 per year for the new Chief Commercial Officer.
- Annual Bonus: Eligible for up to 40% of base salary based on performance.
- Equity Grant: Option to purchase 85,000 shares of common stock, subject to Board approval.
- Vesting Schedule: 25% vests on the first anniversary of the start date (November 15, 2021), with the remainder vesting in equal monthly installments over the subsequent three years.
Material Changes
The primary material change is the appointment of Ken Gelhaus as Chief Commercial Officer, effective November 15, 2021. Mr. Gelhaus brings over 15 years of experience in life sciences and diagnostics, most recently serving as Vice President/General Manager at BD Biosciences and General Manager, Canada at Leica Biosystems.
Outlook, Risks, and Management Commentary
The filing does not provide updated financial guidance, outlook, or specific risk factors. Management commentary is limited to the strategic value of Mr. Gelhaus's experience in commercial operations, strategy development, and acquisition integration. The appointment is intended to strengthen the Company's commercial leadership.
Key Facts for Investor Verification
- Verify the Board of Directors' formal approval of the 85,000 share option grant.
- Confirm the fair market value of the stock on the grant date to determine the exercise price.
- Review the specific performance metrics tied to the 40% annual bonus eligibility.
- Assess the impact of the new executive's background on the Company's commercial strategy in the life sciences sector.